Trial Profile
An open, prospective, single center study of apatinib in the treatment of advanced cholangiocarcinoma
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 12 Jun 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- 12 Jun 2018 New trial record